A261 A Phase 1 Dose-escalation and Pharmacokinetic (PK) Study of a
Novel Spectrum-selective Kinase Inhibitor (SSKI), XL647, in Patients
with Advanced Solid Malignancies. Heather Wakelee, Alex A. Adjei,
Joanne Halsey, Janet Lensing, Julia Dugay, Lorelei Hanson, Joel Reid,
Sylvia Hutchison, Jill Piens, Branimir I. Sikic.
(Tuesday afternoon, 12:30 pm Eastern)
A245 A Phase 1 Study of a Novel Spectrum Selective Kinase Inhibitor
(SSKI), XL880, Administered Orally in Patients with Advanced Solid
Malignancies. Patricia LoRusso, Leonard Appleman, Elizabeth Heath,
Lauren Malburg, Andrew X. Zhu, Martin Carey, Geoffrey I. Shapiro,
Joseph P. Eder.
(ditto)
C82 A Phase 1 Dose-escalation and Pharmacokinetic (PK) Study of a
Novel Spectrum Selective Kinase Inhibitor (SSKI), XL999, in Patients
with Advanced Solid Malignancies. Kyriakos P. Papadopoulos, Monica
M. Mita, Janet Curtright, Afshin Dowlati, Susan Flick, Alejandro Ricart,
Chris Takimoto, Harold Keer, Josh Cooper.
(ditto, except Thursday) |
